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BACKGROUND & AIMS: Little is known about factors
associated with a sustained virologic response (SVR)
among patients with hepatitis C virus (HCV) infection
to treatment with protease inhibitors. METHODS: Pre-
viously untreated patients (from the Serine Protease Inhibi-
tor Therapy 2 [SPRINT-2] trial) and those who did not
respond to prior therapy (from the Retreatment with HCV
Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol
2 [RESPOND-2] trial) received either a combination of
peginterferon and ribavirin for 48 weeks or boceprevir,
peginterferon, and ribavirin (triple therapy) after 4 weeks of
peginterferon and ribavirin (total treatment duration, 28–48
wk). A good response to interferon was defined as a1 log10
decrease in HCV RNA at week 4; a poor response was defined
as a 1 log10 decrease. We used multivariate regression
analyses to identify baseline factors of the host (including
the polymorphism interleukin [IL]-28B rs12979860) associ-
ated with response. The polymorphism IL-28B rs8099917
lso was assessed. RESULTS: In the SPRINT-2 trial, factors
hat predicted a SVR to triple therapy included low viral load
odds ratio [OR], 11.6), IL-28B genotype (rs 12979860 CC vs
T and CT; ORs, 2.6 and 2.1, respectively), absence of cir-
hosis (OR, 4.3), HCV subtype 1b (OR, 2.0), and non-black
ace (OR, 2.0). In the RESPOND-2 trial, the only factor
ignificantly associated with a SVR was previous relapse,
ompared with previous nonresponse (OR, 2.6). Most pa-
ients with rs12979860 CC who received triple therapy had
ndetectable levels of HCV RNA by week 8 (76%–89%), and
ere eligible for shortened therapy. In both studies, IL-28B
s12979860 CC was associated more strongly with a good
esponse to interferon than other baseline factors; however,
1 log10 decrease in HCV-RNA level at week 4 was asso-
iated more strongly with SVR than IL-28B rs12979860.
ombining the rs8099917 and rs12979860 genotypes does
ot increase the association with SVR. CONCLUSIONS:
he CC polymorphism at IL-28B rs12979860 is associ-ted with response to triple therapy and can identify
andidates for shorter treatment durations. A >1 log10
decrease in HCV RNA at week 4 of therapy is the stron-
gest predictor of a SVR, regardless of polymorphisms in
IL-28B. ClinicalTrials.gov; numbers NCT00705432 and
NCT00708500.
Keywords: Clinical Trial; Response to Therapy; Prognostic
Factors; Genetic.
Watch this article’s video abstract and others at http://
tiny.cc/j026c.
Scan the quick response (QR) code to the left with
your mobile device to watch this article’s video ab-
stract and others. Don’t have a QR code reader? Get
one at mobiletag.com/en/download.php.
Baseline predictors of sustained virologic response (SVR) tointerferon-based therapies include interleukin (IL)-28B poly-
orphism, viral load, genotype, age, ethnicity, body weight,
nsulin resistance, steatosis, and fibrosis stage.1–3 On-treatment
iral kinetics have been more predictive of SVR, particularly the
egree of virologic decline at weeks 4 and 12.4,5
In a large prospective study of HCV genotype 1 pa-
tients treated with peginterferon–ribavirin,5 genome-
ide association analysis revealed several host single
ucleotide polymorphisms (SNPs) on chromosome 19,
ear the IL-28B gene, that were associated strongly with
Abbreviations used in this paper: BMI, body mass index; CI, conﬁ-
dence interval; IDEAL, Individualized Dosing Efﬁcacy vs Flat Dosing to
Assess Optimal Pegylated Interferon Therapy; IL, interleukin; OR, odds
ratio; PR48, peginterferon alfa-2b–ribavirin plus boceprevir placebo for
44 weeks; R, ribavirin; RESPOND-2, Retreatment with HCV Serine
Protease Inhibitor Boceprevir and PegIntron/Rebetol 2; RGT, response-
guided therapy; SNP, single nucleotide polymorphism; SPRINT-2, Ser-
ine Protease Inhibitor Therapy 2; SVR, sustained virologic response.
© 2012 by the AGA Institute
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September 2012 PREDICTORS OF RESPONSE WITH BOCEPREVIR 609SVR.3,6 Patients homozygous for the CC allele of the
SNP rs12979860 had higher SVR rates compared with
those with the CT or TT alleles. Differences in genotype
prevalence partially explained the lower SVR rates
among black patients. Several other reports have cor-
roborated these findings.7,8 Another SNP, rs8099917,
also has been reported to show predictive utility for SVR.9
The favorable homozygous TT variant was associated
with higher SVR rates compared with the GT or GG
variants. This assay has now become commercially avail-
able along with the rs12979860. A recent cross-analysis of
these 2 published SNPs found for those with the
rs12979860 CC variant, additional genotyping of the
rs8099917 SNP had no impact on response prediction,
whereas those with the rs12979860 TT variant benefited
with respect to SVR prediction by additional genotyping
of the rs8099917 SNPs.9
Data from 2 large phase 3 trials that assessed the
NS3/4A protease inhibitor, boceprevir, recently were pub-
lished.10,11 SVR rates with boceprevir plus peginterferon–
ibavirin significantly improved SVR compared with
eginterferon–ribavirin control. The boceprevir regimens
sed a 4-week lead-in period with peginterferon–ribavirin
efore adding boceprevir. In multivariate regression anal-
ses, baseline predictors of SVR in previously treated pa-
ients included assignment to a boceprevir group rather
han the control group, previous relapse vs previous non-
esponse, low viral load at baseline, and absence of cirrho-
is. In previously untreated patients, baseline predictors of
VR included assignment to a boceprevir group rather
han the control group, race, low viral load at baseline,
ge, statin use, and absence of cirrhosis. In both studies,
ood response to interferon, defined as a 1 log10 IU/mL
ecline in HCV-RNA level after the 4-week lead-in, was the
trongest predictor of SVR.
The role of IL-28B in combination with other baseline
actors in predicting interferon response, as defined by the
-week peginterferon–ribavirin lead in, and, ultimately,
VR in HCV protease inhibitor– containing regimens, re-
ains undefined.12 We assessed the relationship and util-
ity of baseline factors and their association with SVR and
early viral kinetics in boceprevir-based regimens in previ-
ously untreated and previous treatment-failure genotype
1 hepatitis C patients.
Materials and Methods
Study Design and Objectives
Two phase 3 boceprevir (Victrelis; Merck Sharp & Do-
hme, Corp, Whitehouse Station, NJ) trials in previously un-
treated (SPRINT-2, n  1097) and previous treatment-failure
patients (RESPOND-2, n  403; included relapsers and partial
esponders to peginterferon and ribavirin) have been reported
Supplementary Figure 1).10,11 Previous treatment-failure pa-
ients are patients who previously had a partial response (2
og10 decline in HCV RNA at week 12) to peginterferon–ribavirin
r who relapsed after peginterferon–ribavirin therapy. All pa-
ients received a 4-week lead-in with peginterferon alfa-2b–riba-
irin. Subsequently, the control group received peginterferon llfa-2b–ribavirin plus boceprevir placebo for 44 weeks (PR48);
he second group received peginterferon alfa-2b–ribavirin plus
oceprevir (24 weeks SPRINT-2; 32 weeks RESPOND-2) using
esponse-guided therapy, whereby patients with undetectable
CV-RNA levels at week 8 were eligible for a shorter (28 weeks
PRINT-2; 36 weeks RESPOND-2) duration of total therapy for
apid responders but continuation of peginterferon–ribavirin
herapy to week 48 for slow responders (BOC RGT); and the
hird group received peginterferon alfa-2b–ribavirin plus boce-
revir for 44 weeks (BOC/PR48).
Both studies prospectively consented patients for pharmacog-
nomic testing and collected samples for biomarker identifica-
ion. Two optional consents/sample collections occurred. The
rst one occurred at the onset of the study and consented/
ollected future-use samples in which no specific assay or test
as mentioned in the consent. For patients who did not consent
o pharmacogenomic testing at the onset of the study, an addi-
ional consent/sample collection was initiated specifically for
L-28B/ITPA testing following published data.3 As stated in the
original protocols and data analysis plans (available at http://
www.nejm.org), IL-28B genetic classification of patients would be
evaluated as a predictor of SVR by frequency tables and logistic
regression models. Here, we describe the IL-28B rs12979860 and
s8099917 genotype distribution in the subpopulation of patients with
harmacogenomic samples, evaluate IL-28B rs12979860 genotype as
pretreatment predictor of SVR and early viral kinetics (ie, week
and week 8 response), and assess if IL-28B rs12979860 predicts
SVR after adjusting for on-treatment interferon response (1 vs
1-log10 decline in HCV-RNA level after the 4-week lead-in). In
addition, we assessed the concordance between rs12979860 and
rs8099917 with respect to SVR.
Other previously well-established predictors of response with
pegylated interferon and ribavirin regimens including host and
viral demographics were assessed and included in regression
analysis models to determine how to predict SVR accurately with
boceprevir-based regimens.
Genotyping
IL-28B genotyping for markers rs12979860, rs12980275,
and rs8103142 was performed by Gentris Clinical Genetics, Inc
(Morrisville, NC), using DNA Sanger Sequencing Technology.
Several SNPs in linkage disequilibrium are in this region, and
the principal one evaluated has been the rs12979860 locus.
Genotype data for rs8099917 were generated using the Illu-
mina 1M Duo chip at the Covance Genomic Laboratory
(Seattle, WA).
Statistical Analysis
Analyses were performed on all patients who consented
to pharmacogenomic sampling, had sampling data, and received
at least one dose of placebo or boceprevir. The proportion of
patients achieving SVR and 95% confidence intervals (CI) were
summarized by IL-28B rs12979860 genotype (CC, CT, TT) for
each treatment group, for both studies. SVR rates and 95% CIs
also are displayed by treatment week 4 response (1 log10
decline vs1 log10 decline), as well as treatment week 8 response
undetectable vs detectable).
Three separate multivariate logistic regression analyses were
onducted to evaluate baseline factors, including IL-28B rs12979860
enotype, as predictors of response in patients assigned to re-
eive triple therapy: (1) SVR as the outcome variable; (2) early
n-treatment response as the outcome variable, defined as 1og10 decline vs 1 log10 decline in HCV-RNA level at week 4;
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610 POORDAD ET AL GASTROENTEROLOGY Vol. 143, No. 3and (3) SVR as the outcome variable with early on-treatment
response modeled as a baseline factor (because week 4 was before
the addition of boceprevir). Odds ratio (OR), 95% CI of the ORs,
and chi-square P values from the logistic models are presented.
hese models are considered exploratory and are unadjusted for
ultiple comparisons.
The proportion of patients achieving SVR and 95% CIs also
ere summarized by IL-28B rs8099917 genotype (TT, GT, GG)
or each treatment group, for both studies. In addition, we
erformed a post hoc analysis for all patients with poor response
o interferon (1 log10 decline at week 4), including those who
did not consent to genomic testing, to determine if there are
baseline characteristics that are predictive of SVR for patients
with poor response to interferon.
Results
Baseline and On-Treatment Predictors of SVR
A total of 1048 (previously untreated, SPRINT-2)
and 393 (previous treatment-failure, RESPOND-2) pa-
tients completed the peginterferon–ribavirin lead-in
phase and received at least one dose of boceprevir or
Table 1. Demographic and Baseline Characteristics.
Previously untreated patients (SP
PR48 BOC RGT
(N  217) (N  222)
IL-28B rs12979860 genotype, n (%)
CC 64 (29) 77 (35)
CT 116 (53) 103 (46)
TT 37 (17) 42 (19)
Age, n (%)
40 y 37 (17) 29 (13)
40 y 180 (83) 193 (87)
ale sex, n (%) 121 (56) 136 (61)
ace, n (%)
Black 29 (13) 29 (13)
Non-black 188 (87) 193 (87)
MI, kg/m2
25 79 (36) 57 (26)
25 138 (64) 165 (74)
CV-RNA level, n (%)
400,000 IU/mL 20 (9) 19 (9)
400,000 IU/mL 197 (91) 203 (91)
CV subtype, n (%)a
1a 137 (63) 137 (62)
1b 71 (33) 76 (34)
Other/missing 9 (4) 9 (4)
ETAVIR fibrosis score, n (%)b
F0, F1, or F2 194 (89) 192 (86)
F3 or F4 15 (7) 19 (9)
Missing 8 (4) 11 (5)
revious treatment response, n (%)c
Nonresponse NA NA
Relapse NA NA
OC, boceprevir.
aThe HCV subtype was ascertained by sequencing of the nonstructura
bPossible METAVIR fibrosis scores are as follows: a score of 0 indicate
fibrosis with few septa, 3 indicates numerous septa without cirrhosis
cPrior nonresponse was defined as a decrease in the HCV-RNA level
CV-RNA level throughout the course of prior therapy, without subseque
s an undetectable HCV-RNA level at the end of prior therapy, withouplacebo. Logistic regression analysis to assess predictorsof SVR was performed in patients who consented to
genomic testing (Table 1). IL-28B genotype data at the
rs12979860 locus were available for 653 (62%) and 259
(66%) of SPRINT-2 and RESPOND-2 patients, respectively
(Supplementary Figure 2). The CC genotype was found in
28% (259 of 912), the CT genotype in 54% (491 of 912),
and the TT genotype in 18% (162 of 912) (Table 1). The
baseline demographic characteristics for patients with
rs12979860 data were balanced among the 3 treatment
groups. Baseline characteristics of patients with genomic
testing as well as SVR rates for those who did and did not
consent to genomic testing are shown in Supplementary
Tables 1 and 2. Overall, in both studies, patients who
consented to genomic testing had numerically higher SVR
rates than those who did not consent.
SVR rates by IL-28B rs12979860 genotype for previ-
ously untreated patients and previous treatment-failure
patients are shown in Figure 1. In previously untreated
patients, low baseline viral load (OR, 11.6) was predic-
tive of response, as was favorable IL-28B genotype (rs
T-2) Previous treatment-failure patients (RESPOND-2)
OC/PR48 PR48 BOC RGT BOC/PR48
 214) (N  52) (N  101) (N  106)
55 (26) 13 (25) 28 (28) 22 (21)
15 (54) 29 (56) 62 (62) 66 (62)
44 (21) 10 (19) 11 (11) 18 (17)
36 (17) 2 (4) 3 (3) 3 (3)
78 (83) 50 (96) 98 (97) 103 (97)
24 (58) 36 (69) 67 (66) 77 (73)
36 (17) 4 (8) 9 (9) 9 (8)
78 (83) 48 (92) 92 (91) 97 (92)
72 (34) 8 (15) 23 (23) 29 (27)
42 (66) 44 (85) 78 (77) 77 (73)
11 (5) 4 (8) 6 (6) 3 (3)
03 (95) 48 (92) 95 (94) 103 (97)
38 (64) 31 (60) 55 (54) 60 (57)
70 (33) 21 (40) 46 (46) 44 (42)
6 (2) 0 0 2 (1)
91 (89) 39 (75) 71 (70) 80 (75)
20 (9) 11 (21) 22 (22) 20 (19)
3 (1) 2 (4) 8 (8) 6 (6)
NA 20 (38) 35 (35) 38 (36)
NA 32 (62) 66 (65) 68 (64)
B region.
o fibrosis, 1 indicates portal fibrosis without septa, 2 indicates portal
d 4 indicates cirrhosis.
t least 2 log10 IU/mL by week 12 of prior therapy, but a detectable
ttainment of a sustained virologic response. Prior relapse was defined
bsequent attainment of a sustained virologic response.RIN
B
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September 2012 PREDICTORS OF RESPONSE WITH BOCEPREVIR 611cirrhosis (OR, 4.3), HCV 1b subtype (OR, 2.0), and
non-black race (OR, 2.0) (Table 2). In previous treat-
ment-failure patients, the only significant predictor of
SVR was previous relapse vs previous nonresponse (OR,
2.6). Although in both studies a low baseline viral load
had the largest relative OR, it should be noted that a
small proportion of patients in each study had a viral
load 400,000 (8% [50 of 653] in SPRINT-2 and 5% [13
of 259] in RESPOND-2).
As previously reported for both studies, patients with
poor response to interferon (1 log10 IU/mL decline at
treatment week 4) had substantially lower SVR rates than
those with a good response to interferon (1 log10 IU/mL
decline at treatment week 4), as well as higher rates of
boceprevir-resistance–associated variants.10,11 We there-
fore performed multivariate analysis to assess baseline
factors that predict interferon response. In previously un-
treated patients, baseline predictors of good response to
interferon included IL-28B genotype, low baseline viral
load, absence of cirrhosis, and lower body mass index
(BMI) (Table 2). In previous treatment-failure patients,
baseline predictors of good response to interferon in-
cluded IL-28B genotype and previous relapse vs previous
nonresponse.
Given that in both previously untreated and previous
treatment-failure patients, 28%–38% of patients with poor
response to interferon who received boceprevir achieved
SVR, compared with only 0%– 4% in the peginterferon–
ribavirin control arm, we also compared SVR rates by
baseline characteristics in these poor interferon respond-
ers. Significant differences in SVR rates (Pearson chi-
square test) for patients with poor response to interferon
who received boceprevir (combined studies) were observed
for patients with genotype 1b vs 1a (47% [45 of 96] vs 25%
[44 of 178]; P  .001), METAVIR score F0/1/2 vs F3/4
(38% [84 of 220] vs 17% [8 of 46]; P  .007), and
baseline viral load 800,000 vs 800,000 (69% [11 of
Figure 1. SVR by IL-28B rs12979860 genotype for (A) previously un
(RESPOND-2). BOC, boceprevir.16] vs 31% [82 of 266]; P  .002). Nonsignificantdifferences in SVR were observed for the other baseline
factors considered, including sex, race (black vs non-
black), age (40 vs 40 y), BMI (25, 25 to 30, 30),
and steatosis score (0 vs 0).
When the log10 HCV-RNA decline at week 4 was added
to the logistic regression analysis, it was a significant
predictor of SVR in previously untreated patients (OR,
8.2) as was low baseline viral load (OR, 8.4), absence of
cirrhosis (OR, 3.5), lower BMI (OR, 2.5), and HCV 1b
subtype (OR, 2.1) (Table 2). IL-28B and race were no
longer significant predictors of SVR. In previous treat-
ment-failure patients, the log10 HCV-RNA decline at week
4 was a significant predictor of SVR (OR, 2.7) as was
previous relapse vs previous nonresponse (OR, 2.2). None
of the other baseline factors were significant predictors of
SVR in the presence of the 4-week peginterferon–ribavirin
lead-in.
rs12979860 and rs8099917 IL-28B
Concordance
Analyses of SVR based on 2 SNPs were performed,
rs12979860 and rs8099917 (Supplementary Table 3).
Fewer samples were available and genotyped successfully
at rs8099917, representing 524 (50%) and 229 (58%) of
SPRINT-2 and RESPOND-2 patients, respectively. As with
the rs12979860 SNP, the baseline demographic character-
istics for patients with rs8099917 data were balanced
among the 3 treatment groups. The breakdown of pa-
tients at the rs8099917 locus revealed 57% (426 of 753)
had the favorable TT genotype, with 39% (293 of 753)
having the GT and 5% (34 of 753) having the GG geno-
types. A cross-analysis of rs12979860 and rs8099917 SNPs
revealed that most CC patients at the rs12979860 locus
had the corresponding favorable TT at the rs8099917
locus. However, the converse was not true because TT
patients at rs8099917 were as likely to be CC vs non-CC.
ated patients (SPRINT-2) and (B) previous treatment-failure patientstrePatients with the CT genotype at rs12979860 had TT or
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612 POORDAD ET AL GASTROENTEROLOGY Vol. 143, No. 3GT variants at rs8099917 but were not found to have the
GG variant, whereas those with the unfavorable TT vari-
ant at rs12979860 SNP were more or less evenly distrib-
Table 2. Logistic Regression for Baseline Predictors of SVR, B
Week 4), and Predictors of SVR Including Treatment
Previously untreated patients (SPRINT-2)
Effect OR (95% CI)
Chi square
P value
Logistic regression for baseline predictors of SVR with triple therapy
Baseline HCV-RNA level,
400,000 vs 400,000
11.6 (1.5–87.8) .02
IL-28B rs12979860 genotype,
CC vs TT
2.6 (1.3–5.1) .006
IL-28B rs12979860 genotype,
CC vs CTb
2.1 (1.2–3.7) .01
IL-28B rs12979860 genotype,
CT vs TT
1.2 (0.7–2.2) .48
Cirrhosis, no vs yes 4.3 (1.6–11.9) .004
Genotype, 1b vs 1a/other/
missing
2.0 (1.2–3.4) .005
Race, non-black vs black 2.0 (1.1–3.7) .03
BMI, 30 vs 30 1.6 (1.0–2.5) .07
Logistic regression for baseline predictors of good interferon respons
IL-28B rs12979860 genotype,
CC vs TT
26.5 (7.6–92.6) .0001
IL-28B rs12979860 genotype,
CC vs CTb
16.4 (5.0–55.6) .0001
IL-28B rs12979860 genotype,
CT vs TT
1.6 (0.9–2.9) .12
Baseline HCV-RNA level,
400,000 vs 400,000
10.3 (1.3–80.5) .03
Cirrhosis, no vs yes 3.7 (1.2–11.1) .02
Race, non-black vs black 1.8 (0.9–3.7) .09
Genotype, 1b vs 1a/other/
missing
1.0 (0.6–1.7) .92
BMI, 30 vs 30 0.4 (0.2–0.8) .008
Logistic regression model of predictors of SVR including treatment we
Baseline HCV-RNA level,
400,000 vs 400,000
8.4 (1.0–68.6) .046
Decline in HCV-RNA level at
week 4,  1 vs 1 log10
decline
8.2 (4.5–15.0) .0001
Cirrhosis, no vs yes 3.5 (1.1–11.3) .04
BMI, 30 vs 30 2.5 (1.4–4.2) .001
Genotype, 1b vs 1a/other/
missing
2.1 (1.2–3.6) .01
Race, non-black vs black 1.8 (0.9–3.6) .08
IL-28B rs12979860 genotype,
CC vs TT
1.2 (0.6–2.7) .59
IL-28B rs12979860 genotype,
CC vs CTb
1.1 (0.6–2.1) .76
IL-28B rs12979860 genotype,
CT vs TT
1.1 (0.6–2.2) .73
aBaseline HCV-RNA cut-off value of 800,000 vs 800,000 was use
bComparison obtained from the same model with CT as reference catuted across the TT, GT, and GG variants at the rs8099917SNP. Combining the 2 SNP genotypes did not offer en-
hanced predictability of SVR (Supplementary Table 3),
and although both rs12979860 and rs8099917 have util-
eline Predictors of Interferon Response (1 log10 Decline at
ek 4 Response
Previous treatment failure patients (RESPOND-2)
Effect OR (95% CI)
Chi square
P value
Baseline HCV-RNA level,
800,000 vs 800,000a
2.6 (0.8–8.9) .12
IL-28B rs12979860 genotype,
CC vs TT
2.0 (0.6–6.7) .27
IL-28B rs12979860 genotype,
CC vs CTb
2.3 (1.0–5.5) .06
IL-28B rs12979860 genotype,
CT vs TT
0.86 (0.3–2.5) .77
Cirrhosis, no vs yes 2.0 (0.7–5.3) .18
Genotype, 1b vs 1a/other/
missing
1.1 (0.6–2.1) .77
Race, non-black vs black 1.3 (0.4–4.2) .68
BMI, 30 vs 30 1.42 (0.7–2.8) .33
Previous response, relapser
vs nonresponder
2.6 (1.3–5.0) .006
1 log10 decline at week 4) with triple therapy
IL-28B rs12979860 genotype,
CC vs TT
9.3 (2.3–37.1) .002
IL-28B rs12979860 genotype,
CC vs CTb
3.8 (1.2–12.0) .02
IL-28B rs12979860 genotype,
CT vs TT
2.4 (0.9–6.7) .09
Baseline HCV-RNA level,
800,000 vs 800,000a
3.3 (0.8–12.8) .09
Cirrhosis, no vs yes 1.0 (0.3–3.1) .97
Race, non-black vs black 1.1 (0.3–4.0) .84
Genotype, 1b vs 1a/other/
missing
0.7 (0.3–1.3) .25
BMI, 30 vs 30 1.1 (0.5–2.3) .84
Previous response, relapser
vs nonresponder
2.6 (1.3–5.5) .009
4 response with triple therapy
Baseline HCV-RNA level,
800,000 vs 800,000a
2.3 (0.7–7.9) .20
Decline in HCV-RNA level at
week 4,  1 vs 1 log10
decline
2.7 (1.2–5.7) .01
Cirrhosis, no vs yes 2.1 (0.8–5.7) .16
BMI, 30 vs 30 1.4 (0.7–2.8) .35
Genotype, 1b vs 1a/other/
missing
1.2 (0.6–2.4) .54
Race, non-black vs black 1.3 (0.4–4.3) .71
IL-28B rs12979860 genotype,
CC vs TT
1.3 (0.4–5.0) .65
IL-28B rs12979860 genotype,
CC vs CTb
2.0 (0.8–4.9) .13
IL-28B rs12979860 genotype,
CT vs TT
0.7 (0.2–2.0) .48
Previous response, relapser
vs nonresponder
2.2 (1.1–4.4) .02
obtain a stable model.
ry.as
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including the control groups.
Response Based on rs12979860 IL-28B Status
and Selected Baseline Characteristics
SVR rates based on prior response to therapy (non-
response and relapse), ethnicity, and fibrosis scores for
IL-28B rs12979860 genotypes are shown in Table 3. SVR
ates were highest for prior relapsers in each of the treat-
ent groups for each of the IL-28B genotypes. The
PRINT-2 trial enrolled black and non-black patients
Table 3. SVR Rates by IL-28B rs12979860 Genotype and Se
Previously untreated pa
SVR b
CC
Treatment group
Blacks
(n  16)
Non-blacks
(n  180)
PR48 3/5 (60) 47/59 (80)
BOC RGT 5/8 (62) 58/69 (84)
BOC/PR48 3/3 (100) 41/52 (79)
SVR by METAVIR sco
F0/1/2 F3/4
PR48 43/56 (77) 5/6 (83)
BOC RGT 61/71 (86) 1/4 (25)
BOC/PR48 38/49 (78) 5/5 (100)
Previous treatment failure p
SVR b
Blacks
(n  6)
Non-blacks
(n  57)
PR48 1/2 (50) 5/11 (45)
BOC RGT 2/3 (67) 20/25 (80)
BOC/PR48 0/1 (0) 17/21 (81)
SVR by prior resp
Prior
nonresponse Prior relapse
PR48 1/3 (33) 5/10 (50)
BOC RGT 5/8 (62) 17/20 (85)
BOC/PR48 4/7 (57) 13/16 (87)
BOC groups combined 9/15 (60) 30/35 (86)
SVR by METAVIR sco
F0/1/2 F3/4
PR48 4/10 (40) 1/2 (50)
BOC RGT 14/17 (82) 8/9 (89)
BOC/PR48 11/14 (79) 4/6 (67)
BOC, boceprevir; n, number of patients who achieved SVR; m, numbe
aPossible METAVIR fibrosis scores are as follows: a score of 0 indicate
fibrosis with few septa, 3 indicates numerous septa without cirrhosis
bPrior nonresponse was defined as a decrease in the HCV-RNA level
CV-RNA level throughout the course of prior therapy, without subseque
s an undetectable HCV-RNA level at the end of prior therapy, withoueparately to better assess differences in treatment effi-acy. Consistent with the results for Caucasians, black
atients with the CC genotype had higher SVR rates than
on-CC, regardless of the treatment regimen. Fibrosis
tage did not appear to influence results, although there
ere a limited number of patients with advanced fibrosis.
Response Based on rs12979860 IL-28B Status
and Early Viral Kinetics
On-treatment differences in viral load reduction
between genotypes were noted immediately after the
addition of boceprevir to peginterferon–ribavirin (Fig-
ted Baseline Characteristics
ts (SPRINT-2), n/m (%)
ce and IL-28B rs12979860 genotype
CT TT
Blacks
(n  40)
Non-blacks
(n  294)
Blacks
(n  38)
Non-blacks
(n  85)
5/15 (33) 28/101 (28) 0/9 (0) 10/28 (36)
3/8 (37) 64/95 (67) 6/13 (46) 17/29 (59)
9/17 (53) 73/98 (74) 8/16 (50) 18/28 (64)
F0/1/2 vs F3/4 and IL-28B rs12979860 genotype
F0/1/2 F3/4 F0/1/2 F3/4
/103 (30) 1/8 (12) 8/35 (23) 1/1 (100)
9/89 (66) 5/10 (50) 20/32 (62) 1/5 (20)
/104 (76) 2/9 (22) 22/38 (58) 4/6 (67)
nts (RESPOND-2), n/m (%)
ce and IL-28B rs12979860 genotype
Blacks
(n  7)
Non-blacks
(n  150)
Blacks
(n  9)
Non-blacks
(n  30)
/2 (0) 5/27 (19) 0/0 (0) 5/10 (50)
/2 (100) 36/60 (60) 2/4 (50) 4/7 (57)
/3 (33) 47/63 (75) 4/5 (80) 9/13 (69)
e to therapyb and IL-28B rs12979860 genotype
Prior
nresponse Prior relapse
Prior
nonresponse Prior relapse
0/14 (0) 5/15 (33) 1/3 (33) 4/7 (57)
2/23 (52) 26/39 (67) 1/4 (25) 5/7 (71)
4/24 (58) 34/42 (81) 4/7 (57) 9/11 (82)
6/47 (55) 60/81 (74) 5/11 (45) 14/18 (78)
F0/1/2 vs F3/4 and IL-28B rs12979860 genotype
F0/1/2 F3/4 F0/1/2 F3/4
4/21 (19) 1/7 (14) 5/8 (62) 0/2 (0)
1/47 (66) 5/10 (50) 5/7 (71) 1/3 (33)
9/55 (71) 8/9 (89) 10/11 (91) 2/5 (40)
patients with indicated IL-28B genotype in the respective subgroup.
o fibrosis, 1 indicates portal fibrosis without septa, 2 indicates portal
d 4 indicates cirrhosis.
at least 2 log10 IU/mL by week 12 of prior therapy but a detectable
ttainment of a sustained virologic response. Prior relapse was defined
bsequent attainment of a sustained virologic response.lec
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614 POORDAD ET AL GASTROENTEROLOGY Vol. 143, No. 3strongest predictor of interferon response, and inter-
feron response ultimately was the strongest predictor of
SVR. As shown in Figure 3, almost all of the patients
with the IL-28B CC genotype had good response to
nterferon (97% [190 of 195] previously untreated; 94%
59 of 63] previous treatment failures). Patients with
he rs12979860 CT or TT genotypes who received bo-
eprevir-containing regimens and showed good re-
ponse to interferon had SVR rates of 67%– 85% vs
8%– 62% for those with the CT or TT genotypes who
Figure 2. Median reductions in viral load from baseline on the basis of rs
nd (B) previous treatment-failure patients (RESPOND-2). Bars represeneceived control (Figure 3A and C).In the response-guided therapy groups of both stud-
ies (BOC RGT), the duration of therapy was based on a
prespecified decision point whereby those with unde-
tectable HCV-RNA levels at week 8 were eligible for
shorter therapy. The majority of CC patients treated
with boceprevir-containing regimens had undetectable
HCV-RNA levels by week 8 (89% [117 of 132] in
SPRINT-2; 76% [38 of 50] in RESPOND-2), and hence
were eligible for shortened duration of therapy (Sup-
plementary Table 4). A lower proportion of patients
79860 IL-28B genotype for (A) previously untreated patients (SPRINT-2)
5th and 75th percentiles. BOC, boceprevir.129with the CT (53% [115 of 218] in SPRINT-2; 46% [59 of
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September 2012 PREDICTORS OF RESPONSE WITH BOCEPREVIR 615128] in RESPOND-2) and TT (42% [36 of 86] in
SPRINT-2; 63% [12 of 19] in RESPOND-2) genotypes
became undetectable by week 8; however, SVR rates for
patients in the boceprevir groups who become unde-
tectable by week 8 were 81%–100%, regardless of IL-28B
genotype (Figure 3B and D). For the patients with poor
response to interferon who received boceprevir, none
with a 3 log10 decline in HCV RNA at week 8 (0 of 44
patients) achieved SVR (Figure 4). Despite having a 1
log10 decline at week 4, 40 of 264 patients had unde-
tectable HCV RNA at week 8 and 83% (33 of 40 pa-
tients) achieved SVR.
Discussion
These predefined analyses assessed baseline predic-
tors of SVR, including both IL-28B rs12979860 and
rs8099917 SNPs, with direct-acting antiviral therapy.
These data suggest that pretreatment knowledge of IL-28B
can be used to predict which patients will be interferon
responsive, and which patients may qualify for a shorter
duration of treatment. However, a 1-log10 HCV RNA
ecline at week 4 was shown to be the strongest overall
Figure 3. SVR by IL-28B rs12979860 genotype and HCV-RNA level a
untreated patients (SPRINT-2) and (C and D) previous treatment-failure
ot included. BOC, boceprevir.redictor of SVR. nIn previously untreated patients (SPRINT-2), those
ith the favorable rs12979860 CC genotype had similar
VR rates across the 3 treatment arms. Despite a similar
VR in all groups with the favorable CC genotype, the
ddition of boceprevir allowed shortening of the total
reatment duration from 48 to 28 weeks in nearly 90% of
atients. The largest relative gain in efficacy for bocepre-
ir-treated patients (BOC RGT or BOC/PR48 groups) over
ontrol (PR48) occurred in patients with the less favorable
s12979860 CT and TT genotypes. Because 83% (78 of 94)
f the black and 68% (379 of 559) of the non-black
atients in SPRINT-2 had the CT or TT genotype, the
ajority of patients would benefit from boceprevir-based
herapy in terms of increased SVR (59% to 71%) compared
ith peginterferon–ribavirin alone (27% to 28%), and an
dded benefit of shortened treatment duration in some.
The current findings show that boceprevir confers a
ubstantial increase in SVR vs peginterferon–ribavirin
lone in prior relapsers and nonresponders to peginter-
eron–ribavirin therapy. Among patients with IL-28B data,
rior relapsers had SVR rates of 74%– 86% with boceprevir
ontaining regimens compared with 45%– 60% for prior
ek 4 and by HCV-RNA detectability at week 8 for (A and B) previously
ents (RESPOND-2). Patients with missing data at week 4 or week 8 aret we
pationresponders. For prior nonresponders and relapsers
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616 POORDAD ET AL GASTROENTEROLOGY Vol. 143, No. 3with the CC genotype, the addition of boceprevir resulted
in SVR rates of 77%–79% vs 46% for peginterferon–ribavi-
rin alone, and allowed a shortened total duration of ther-
apy to 36 weeks in 76%. Robust comparisons based on
race, fibrosis stage, and prior response to therapy were not
possible owing to a limited number of patients within
some subsets. Despite this limitation, overall data suggest
patients with advanced fibrosis will have a higher likeli-
hood of achieving SVR if boceprevir is added to peginter-
feron–ribavirin, regardless of IL-28B genotype.
The addition of boceprevir to poor interferon respond-
ers led to significantly improved SVR rates (28% to 38%)
compared with only 0%– 4% for those treated with pegin-
terferon-ribavirin alone. However, host and viral baseline
predictors further delineate this group of poor respond-
ers. Patients with poor response to interferon were almost
twice as likely to achieve SVR if they were genotype 1b vs
1a, had a METAVIR score F0/1/2 vs F3/4, or baseline viral
load 2 M IU/mL vs 2 M IU/mL. Indeed, these geno-
type 1b patients had SVR rates of close to 50%. For this
population of poorly interferon-responsive patients, a 3
log10 decline by week 8 (corresponding to 4 weeks of triple
herapy) had a negative predictive value of 100% for
chieving SVR. Hence, triple therapy for those with poor
nterferon response can be as short as 8 weeks, an impor-
ant early futility time point.
This study had limitations. Approximately one third of
atients in these 2 large trials did not consent to genomic
esting and the studies were neither designed nor powered
o assess the impact of IL-28B genotype on SVR. The
ubpopulation with IL-28B data was not a random sam-
ling and there were some small differences between the
roup that consented to pharmacogenomic testing and
he overall study population. In addition, the SVR rate in
he CC control patients of SPRINT-2 (78%) was higher
han some previous reports of 69% (Caucasians), 48%African Americans), 56% (Hispanics), and 66% (all races
ombined),6 and SVR rates for patients in the control and
boceprevir arms of both studies who consented to
genomic testing were higher than those who did not
consent. Therefore, there may have been consent bias
because some patients consented to testing after begin-
ning treatment and the study may have underestimated
an incremental impact of boceprevir on SVR in patients
with the IL-28B rs1299860 CC genotype. It should be
noted that the proportion of patients who consented
prospectively for pharmacogenomic testing was similar to
the large, US phase 3b Individualized Dosing Efficacy vs
Flat Dosing to Assess Optimal Pegylated Interferon Ther-
apy (IDEAL) study of peginterferon–ribavirin therapy
(57%), and in the IDEAL study the decision to consent for
pharmacogenomic testing did not introduce selection
bias.6,13 The current analyses also did not consider adher-
nce to treatment regimen. However, a prior study showed
hat 57% and 61% of patients in SPRINT-2 and RE-
POND-2 were compliant with boceprevir dosing (80%)
nd dosing duration (80%).14 The study showed that
treatment duration was an important factor associated
with SVR, and the recommended 7- to 9-hour boceprevir
dosing interval had minimal impact on SVR in patients
with more than 80% adherence to dosing.
These data suggest that knowledge of IL-28B genotype
pretreatment may be used to predict which patients will
have the highest likelihood of receiving a shorter duration
of triple therapy, and of SVR itself. These data also sug-
gest that IL-28B at the rs12979860 locus is the strongest
pretreatment predictor of interferon responsiveness,
whereas the decline in HCV-RNA level at week 4 com-
pared with baseline is an on-treatment measurement of
interferon responsiveness, and is ultimately the best over-
all predictor of SVR. The IL-28B rs8099917 locus appears
Figure 4. Sustained virologic
response in patients with poor
response to interferon (1 log10
decline in HCV RNA after a
4-week peginterferon-ribavirin
lead-in) based on treatment
week 8 response (log decline in
viral load compared with base-
line viral load, BOC RGT and
BOC/PR48 arms combined).
BOC, boceprevir.to have less overall utility as a single marker, or in com-
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September 2012 PREDICTORS OF RESPONSE WITH BOCEPREVIR 617bination with rs12979860, in the patient population stud-
ied. The use of IL-28B testing is common now in clinical
rials, but its role in practice still is evolving. More potent
egimens or an interferon-free regimen may further atten-
ate or even obviate the need for baseline predictors of
esponse, including IL-28B testing.
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Note: To access the supplementary material
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September 2012 PREDICTORS OF RESPONSE WITH BOCEPREVIR 618.e3Supplementary Table 1. Demographics and Baseline Characteristics of the Overall Study Populations and the IL-28B
rs12979860 Pharmacogenomic Subpopulations
Previously untreated patients (SPRINT-2)
PR48 BOC RGT BOC/PR48
In IL-28B
analysis
population
(n  217)
Not in IL-
28B
analysis
population
(n  127)
Total
(N  344)
In IL-28B
analysis
population
(n  222)
Not in IL-
28B
analysis
population
(n  128)
Total
(N  350)
In IL-28B
analysis
population
(n  214)
Not in IL-
28B
analysis
population
(n  140)
Total
(N  354)
IL-28B rs12979860 genotype, n (%)
CC 64 (29) NA NA 77 (35) NA NA 55 (26) NA NA
CT 116 (53) NA NA 103 (46) NA NA 115 (54) NA NA
TT 37 (17) NA NA 42 (19) NA NA 44 (21) NA NA
Age, n (%)
40 y 37 (17) 19 (15) 56 (16) 29 (13) 15 (12) 44 (13) 36 (17) 17 (12) 53 (15)
40 y 180 (83) 108 (85) 288 (84) 193 (87) 113 (88) 306 (87) 178 (83) 123 (88) 301 (85)
Male sex, n (%) 121 (56) 78 (61) 199 (58) 136 (61) 86 (67) 222 (63) 124 (58) 87 (62) 211 (60)
Race, n (%)
Black 29 (13) 18 (14) 47 (14) 29 (13) 18 (14) 47 (13) 36 (17) 19 (14) 55 (16)
Non-black 188 (87) 109 (86) 297 (86) 193 (87) 110 (86) 303 (87) 178 (83) 121 (86) 299 (84)
BMI, kg/m2
25 79 (36) 45 (35) 124 (36) 57 (26) 39 (30) 96 (27) 72 (34) 48 (34) 120 (34)
25 138 (64) 82 (65) 220 (64) 165 (74) 89 (70) 254 (73) 142 (66) 92 (66) 234 (66)
HCV-RNA level, n (%)
400,000 IU/mL 20 (9) 26 (8) 6 (5) 19 (9) 10 (8) 29 (8) 11 (5) 13 (9) 24 (7)
400,000 IU/mL 197 (91) 121 (95) 318 (92) 203 (91) 118 (92) 321 (92) 203 (95) 127 (91) 330 (93)
HCV subtype, n (%)a
1a 137 (63) 79 (62) 216 (63) 137 (62) 86 (67) 223 (64) 138 (64) 92 (66) 230 (65)
1b 71 (33) 43 (34) 114 (33) 76 (34) 41 (32) 117 (33) 70 (33) 42 (30) 112 (32)
Other/missing 9 (4) 5 (4) 14 (4) 9 (4) 1 (1) 10 (3) 6 (2) 6 (4) 12 (3)
METAVIR fibrosis score, n (%)b
F0, F1, or F2 194 (89) 117 (92) 311 (90) 192 (86) 110 (86) 302 (86) 191 (89) 111 (79) 302 (85)
F3 or F4 15 (7) 8 (6) 23 (7) 19 (9) 14 (11) 33 (9) 20 (9) 22 (16) 42 (12)
Missing 8 (4) 2 (2) 10 (3) 11 (5) 4 (3) 15 (4) 3 (1) 7 (5) 10 (3)
Previous treatment failure patients (RESPOND-2)
(n  52) (n  26) (N  78) (n  101) (n  55) (N  156) (n  106) (n  54) (N  160)
IL-28B rs12979860 genotype, n (%)
CC 13 (25) NA NA 28 (28) NA NA 22 (21) NA NA
CT 29 (56) NA NA 62 (61) NA NA 66 (62) NA NA
TT 10 (19) NA NA 11 (11) NA NA 18 (17) NA NA
Age, n (%)
40 y 2 (4) 2 (8) 4 (5) 3 (3) 2 (4) 5 (3) 3 (3) 4 (7) 7 (4)
40 y 50 (96) 24 (92) 74 (95) 98 (97) 53 (96) 151 (97) 103 (97) 50 (93) 153 (96)
Male sex, n (%) 36 (69) 21 (81) 57 (73) 67 (66) 28 (51) 95 (61) 77 (73) 35 (65) 112 (70)
Race, n (%)
Black 4 (8) 8 (31) 12 (15) 9 (9) 9 (16) 18 (12) 9 (8) 9 (17) 18 (11)
Non-black 48 (92) 18 (69) 66 (85) 92 (91) 46 (84) 138 (88) 97 (92) 45 (83) 142 (89)
BMI, kg/m2
25 8 (15) 11 (42) 19 (24) 23 (23) 11 (20) 34 (22) 29 (27) 15 (28) 44 (27)
25 44 (85) 15 (58) 59 (76) 78 (77) 44 (80) 122 (78) 77 (73) 39 (72) 116 (73)
CV-RNA level, n (%)
400,000 IU/mL 4 (8) 1 (4) 5 (6) 6 (6) 1 (2) 7 (4) 3 (3) 4 (7) 7 (4)
400,000 IU/mL 48 (92) 25 (96) 73 (94) 95 (94) 54 (98) 149 (96) 103 (97) 50 (93) 153 (96)
CV subtype, n (%)a
1a 31 (60) 14 (54) 45 (58) 55 (54) 34 (62) 89 (57) 60 (57) 35 (65) 95 (59)
1b 21 (40) 12 (46) 33 (42) 46 (46) 19 (35) 65 (42) 44 (42) 17 (31) 61 (38)
Unknown/missing 0 0 0 0 2 (3) 2 (1) 2 (1) 2 (4) 4 (3)
ETAVIR fibrosis score, n (%)b
F0, F1, or F2 39 (75) 21 (81) 60 (77) 71 (70) 40 (73) 111 (71) 80 (75) 39 (72) 119 (74)
F3 or F4 11 (21) 3 (12) 14 (18) 22 (22) 10 (18) 32 (21) 20 (19) 10 (19) 30 (19)
Missing 2 (4) 2 (8) 4 (5) 8 (8) 5 (9) 13 (8) 6 (6) 5 (9) 11 (7)
H
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Previous treatment failure patients (RESPOND-2)
PR48 BOC RGT BOC/PR48
In IL-28B
analysis
population
(n  217)
Not in IL-
28B
analysis
population
(n  127)
Total
(N  344)
In IL-28B
analysis
population
(n  222)
Not in IL-
28B
analysis
population
(n  128)
Total
(N  350)
In IL-28B
analysis
population
(n  214)
Not in IL-
28B
analysis
population
(n  140)
Total
(N  354)
Previous treatment response, n (%)c
Nonresponse 20 (38) 9 (35) 29 (37) 35 (35) 19 (35) 54 (35) 38 (36) 19 (35) 57 (36)
Relapse 32 (62) 17 (65) 49 (63) 66 (65) 36 (65) 102 (65) 68 (64) 35 (65) 103 (64)
BOC, boceprevir.
aThe HCV subtype was ascertained by sequencing of the nonstructural 5B region.
bPossible METAVIR fibrosis scores are as follows: a score of 0 indicates no fibrosis, 1 indicates portal fibrosis without septa, 2 indicates portal
fibrosis with few septa, 3 indicates numerous septa without cirrhosis, and 4 indicates cirrhosis.
cPrior nonresponse was defined as a decrease in the HCV-RNA level of at least 2 log10 IU/mL by week 12 of prior therapy but a detectable
CV-RNA level throughout the course of prior therapy, without subsequent attainment of a sustained virologic response. Prior relapse was defined
s an undetectable HCV-RNA level at the end of prior therapy, without subsequent attainment of a sustained virologic response.Supplementary Table 2. SVR for Patients in the IL-28B
rs12979860 Analysis Population,
and Not in the IL-28B rs12979860
Analysis Population
Treatment
arm
In the IL-28B
rs12979860
analysis population
Not in the IL-28B
rs12979860
analysis population
Previously untreated patients (SPRINT-2), n/m (%)
PR48 93/217 (43) 44/127 (35)
BOC RGT 153/222 (69) 80/128 (63)
BOC/PR48 152/214 (71) 90/140 (64)
Previous treatment failure patients (RESPOND-2), n/m (%)
PR48 16/52 (31) 1/26 (4)
BOC RGT 66/101 (65) 29/55 (53)
BOC/PR48 78/106 (74) 29/54 (54)
n, number of patients who achieved SVR; m, number of patients in the
indicated population.
PP
n
i
September 2012 PREDICTORS OF RESPONSE WITH BOCEPREVIR 618.e5Supplementary Table 3. SVR by IL-28B rs12979860 and IL-28B rs8099917 Genotype
rs12979860, n/m (% with SVR)
rs8099917 CC CT TT Total
Previously untreated patients (SPRINT-2)
PR48
TT 41/50 (82) 12/45 (27) 0/10 (0) 53/105 (50)
GT 0/1 (0) 15/51 (29) 5/14 (36) 20/66 (30)
GG 0 0 3/5 (60) 3/5 (60)
Total 41/51 (80) 27/96 (28) 8/29 (28)
BOC groups combined
TT 89/107 (83) 58/76 (76) 14/24 (58) 161/207 (78)
GT 0/1 (0) 66/96 (69) 14/22 (64) 80/119 (67)
GG 0 0 11/22 (50) 11/22 (50)
Total 89/108 (82) 124/172 (72) 39/68 (57)
Previous treatment-failure patients (RESPOND-2)
PR48
TT 5/11 (45) 1/10 (10) 1/2 (50) 7/23 (30)
GT 0 3/18 (17) 3/7 (43) 6/25 (24)
GG 0 0 0 0
Total 5/11 (45) 4/28 (14) 4/9 (44)
BOC groups combined
TT 30/40 (75) 21/38 (55) 8/13 (62) 59/91 (65)
GT 0 54/77 (70) 4/6 (67) 58/83 (70)
GG 0 0 5/7 (71) 5/7 (71)
Total 30/40 (75) 75/115 (65) 17/26 (65)NOTE. Because of the small number of patients with rs8099917 data, the boceprevir groups were combined.Supplementary Table 4. Week 8 Response (Detectable vs Undetectable) by IL-28B rs12979860 Status for Patients Treated
With Boceprevir
Treatment
group
Proportion of patients
CC CT TT
HCV-RNA
detectable at
week 8
HCV-RNA
undetectable at
week 8
HCV-RNA
detectable at
week 8
HCV-RNA
undetectable at
week 8
HCV-RNA
detectable at
week 8
HCV-RNA
undetectable at
week 8
reviously untreated patients (SPRINT-2), n/m (%)
BOC RGT 8/77 (10) 66/77 (86) 48/103 (47) 52/103 (50) 23/42 (55) 19/42 (45)
BOC/PR48 2/55 (4) 51/55 (93) 47/115 (41) 63/115 (55) 22/44 (50) 17/44 (39)
revious treatment failure patients (RESPOND-2), n/m (%)
BOC RGT 6/28 (21) 21/28 (75) 31/62 (50) 25/62 (40) 7/11 (64) 3/11 (27)
BOC/PR48 5/22 (23) 17/22 (77) 29/66 (44) 34/66 (52) 9/18 (50) 9/18 (50)
, number of patients with detectable or undetectable HCV-RNA level at week 8 and who had nonmissing data; m, number of patients with
ndicated IL-28B rs12979860 genotype.
